Serving leading biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving leading biopharmaceutical companies globally:
Generated: October 22, 2017
What is the competitive landscape for BAUSCH AND LOMB, and what generic alternatives to BAUSCH AND LOMB drugs are available?
BAUSCH AND LOMB has seventy-five approved drugs.| International Patents: | 142 |
| US Patents: | 22 |
| Tradenames: | 64 |
| Ingredients: | 53 |
| NDAs: | 75 |
Export unavailable in trial.
Subscribe for complete access.
Export unavailable in trial.
Subscribe for complete access.
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
bepotastine besilate | Ophthalmic Solution | 1.5% | BEPREVE | 9/9/2013 |
bromfenac sodium | Ophthalmic Solution | 0.07% | PROLENSA | 7/26/2013 |
timolol maleate | Ophthalmic Solution | 0.5% | ISTALOL | 10/19/2012 |
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7,056,893 | Topical treatment for prevention of ocular infections | ► Subscribe | |||||||||||||
| 8,497,304 | Aqueous liquid preparation containing 2-amino-3-(4-bromobenzoyl)phenylacetic acid | ► Subscribe | |||||||||||||
| 6,307,052 | Acid-addition salts of optically active piperidine compound and process for producing the same | ► Subscribe | |||||||||||||
| 8,252,307 | Method for treating and/or preventing retinal diseases with sustained release corticosteroids | ► Subscribe | |||||||||||||
| 7,282,589 | Acid addition salt of optically active piperidine compound and process for preparing the same | ► Subscribe | |||||||||||||
| 8,883,825 | Aqueous liquid preparations and light-stabilized aqueous liquid preparations | ► Subscribe | |||||||||||||
| 6,239,113 | Topical treatment or prevention of ocular infections | ► Subscribe | |||||||||||||
| 6,569,443 | Topical treatment or prevention of ocular infections | ► Subscribe | |||||||||||||
| 7,732,415 | Topical treatment or prevention of ocular infections | ► Subscribe | |||||||||||||
| 7,749,970 | Topical treatment of prevention of ocular infections | ► Subscribe | |||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Country | Document Number | Estimated Expiration | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Austria | 528003 | ► Subscribe | |||||||||||||
| China | 1612734 | ► Subscribe | |||||||||||||
| South Korea | 101016595 | ► Subscribe | |||||||||||||
| Germany | 69839152 | ► Subscribe | |||||||||||||
| European Patent Office | 1525884 | ► Subscribe | |||||||||||||
| South Korea | 20030092108 | ► Subscribe | |||||||||||||
| Mexico | 2011009758 | ► Subscribe | |||||||||||||
| Japan | 3631748 | ► Subscribe | |||||||||||||
| Hong Kong | 1083468 | ► Subscribe | |||||||||||||
| Malaysia | 118016 | ► Subscribe | |||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 780 | Luxembourg | ► Subscribe | PRODUCT NAME: TRASTUZUMAB ET HYALURONIDASE HUMAINE RECOMBINANTE; FIRST REGISTRATION DATE: 20130826 | ||||||||||||
| C/GB99/043 | United Kingdom | ► Subscribe | PRODUCT NAME: DORZOLAMIDE OR AN OPHTHALMOLOGICALLY ACCEPTABLE SALT THEREOF, PREFERABLY DORZOLAMIDE HYDROCHOLORIDE, PLUS TIMOLOL OR AN OPHTHAMOLOGICALLY ACCEPTABLE SALT THEREOF, PREFERABLY TIMOLOL MALEATE; REGISTERED: DK 19045 19980306; UK PL 00025/0373 19980804 | ||||||||||||
| C0111 | Belgium | ► Subscribe | PRODUCT NAME: LATANOPROSTUM; NAT. REGISTRATION NO/DATE: 277 IS 271 F 13 19970617; FIRST REGISTRATION: SE 12716 1996071 | ||||||||||||
| 14/041 | Ireland | ► Subscribe | PRODUCT NAME: BRIMONIDINE AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF; REGISTRATION NO/DATE: EU/1/13/904 20140221 | ||||||||||||
| 2016 00031 | Denmark | ► Subscribe | PRODUCT NAME: RITUXIMAB AND RECOMBINANT HUMAN HYALURONIDASE; REG. NO/DATE: EU/1/98/067 20140326 | ||||||||||||
| 80016 | Netherlands | ► Subscribe | PRODUCT NAME: LEVOFLOXACINE, DESGEWENST IN DE VORM VAN EEN SOLVAAT, IN HET BIJZONDER LEVOFLOXACINE-HEMIHYDRAAT; NAT. REGISTRATION NO/DATE: RVG 21810 - RVG 21812 19971209; FIRST REGISTRATION: GB 13402/0011 - 13402/0013 19970606 | ||||||||||||
| 2016000049 | Germany | ► Subscribe | PRODUCT NAME: RITUXIMAB UND REKOMBINANTE HUMANE HYALURONIDASE; NAT. REGISTRATION NO/DATE: EU/1/98/067/003 20140321; FIRST REGISTRATION: EU EU/1/98/067/003 20140621 | ||||||||||||
| 90018-0 | Sweden | ► Subscribe | PRODUCT NAME: BROMFENAK; REG. NO/DATE: EU/1/11/692/001 20110518 | ||||||||||||
| 0683 | Netherlands | ► Subscribe | PRODUCT NAME: BRIMONIDINE EN FARMACEUTISCH AANVAARDBARE ZOUTEN DAARVAN VOOR TOEPASSING ALS GENEESMIDDEL VOOR DE BEHANDELING VAN DOOR ROSACEA GEINDUCEERDE ROODHEID; REGISTRATION NO/DATE: EU/1/13/904 20140225 | ||||||||||||
| 90031-1 | Sweden | ► Subscribe | PRODUCT NAME: LATANOPROST | ||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 22,990 others who get our Drug Patent Expiration Alerts:
